Urothelial Cancer

Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.

Guru P. Sonpavde, MD, discusses the AMBASSADOR trial of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma.

Thomas Powles, MBBS, MRCP, MD, discusses how avelumab maintenance in bladder cancer has been challenging. Specifically in sequenced immune therapy, there was a 25% decrease in patient deaths, but only 50% of the patients survived. Powles also introduces the anatomy of an antibody-drug conjugate (ADC).

Thomas Powles, MBBS, MRCP, MD, discusses how the KEYNOTE-361 trial failed because of the trial’s design. Data show that the maintenance phase of the trial is what was driving the benefit and that the longest survival with this trial was 17 months with both pembrolizumab and chemotherapy treatment rather than just chemotherapy.

Guru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Thomas Powles, MBBS, MRCP, MD, discusses how different trials have been used to study urothelial cancer (UC) treatments, including DANUBE, IMvigor130, and KEYNOTE-361, all of which are frontline, randomized, phase 3 studies that were unsuccessful. A trial that had better results involved nivolumab plus gemcitabine/cisplatin, due to patients being in better physical condition to withstand chemotherapy.

Thomas Powles, MBBS, MRCP, MD, discusses how upon examining an elderly patient experiencing hematuria, they were found to have had a transurethral resection of a bladder tumor, which revealed the presence of muscle-invasive bladder cancer. The patient is determined to have metastatic disease and is ineligible for cisplatin chemotherapy in the first line.

Janaki Neela Sharma, MD, discusses the implications of treatment advances in the front line for patients with advanced bladder cancer.

Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

Ami Umesh Badami, MD, discusses the factors that guide treatment decision-making for patients with clear cell or non–clear cell renal cell carcinoma.

Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.

Janaki Neela Sharma, MD, discusses which trials have shifted the therapeutic paradigm for patients with urothelial cancer.

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.

Ami Umesh Badami, MD, discusses a case study illustrating key decisions in the treatment of metastatic renal cell carcinoma.

Janaki Neela Sharma, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced/metastatic bladder cancer.

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.